![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » CanSino to Launch Phase 3 COVID-19 Vaccine Trial in Saudi Arabia
CanSino to Launch Phase 3 COVID-19 Vaccine Trial in Saudi Arabia
August 11, 2020
China-based CanSino Biologics is preparing a phase 3 trial of its COVID-19 vaccine in Saudi Arabia, the country’s Ministry of Health has announced.
The study will include at least 5,000 healthy participants over age 18, who will be given either a low dose of the vaccine or the vaccine without any active ingredients.
CanSino’s vaccine, Ad5-nCoV, has shown efficacy in early phase trials, generating antibodies and good immune responses in the volunteers. The company announced positive results from a phase 2 trial last month, showing immune responses in more than 90 percent of participants following a single dose with no serious adverse reactions (DID, July 21).
In March, Ad5-nCoV became the first COVID-19 vaccine candidate to undergo human testing in China. However, it now lags behind two other China-based competitors, Sinovac and Sinopharm, which have already begun phase 3 testing of their vaccines overseas. — Jordan Williams
Upcoming Events
-
21Oct